Mepolizumab significantly reduced the annualized rate of moderate or severe exacerbations in COPD with an eosinophilic phenotype. Some 20% to 40% of COPD patients have elevated blood eosinophil counts ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback